这篇文章不错，转发给_老虎社区_美港股上老虎

2021-06-25

这篇文章不错，转发给大家看

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":122462210,"tweetId":"122462210","gmtCreate":1624630496330,"gmtModify":1624630496330,"author":{"id":3584062924373387,"idStr":"3584062924373387","authorId":3584062924373387,"authorIdStr":"3584062924373387","name":"西奈山","avatar":"https://static.tigerbbs.com/f758418a1214cda30f0694d1cc9b272a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\n这篇文章不错，转发给大家看</body></html>","htmlText":"<html><head></head><body>\n这篇文章不错，转发给大家看</body></html>","text":"这篇文章不错，转发给大家看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/122462210","repostId":2146802114,"repostType":2,"repost":{"id":"2146802114","kind":"news","pubTimestamp":1624586055,"share":"https://www.laohu8.com/m/news/2146802114?lang=&edition=full","pubTime":"2021-06-25 09:54","market":"us","language":"zh","title":"《新股消息》康诺亚生物(02162.HK)今日起招股  入场费26,918.55元","url":"https://stock-news.laohu8.com/highlight/detail?id=2146802114","media":"AAFN","summary":"内地生物科技公司康诺亚生物-B公布招股详情，计划发售5,826.45万股股份，当中约10%在港公开发售，招股价介乎50.5元至53.3元，每手500股，入场费26,918.55元，由今日起至下周三公开招股，预计於7月8日上市。候选药物目前均处於开发阶段。","content":"<html><body><p>内地生物科技公司康诺亚生物-B(02162.HK)公布招股详情，计划发售5,826.45万股股份，当中约10%在港公开发售，招股价介乎50.5元至53.3元，每手500股，入场费26,918.55元，由今日(25日)起至下周三(30日)公开招股，预计於7月8日上市。<a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>、中金及华泰国际为联席保荐人。公司专注於自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法，核心产品CM310，用於治疗多种过敏性疾病，如中重度特应性皮炎(AD)、中重度嗜酸性哮喘和慢性鼻窦炎伴鼻息肉(CRSwNP)以及潜在慢性阻塞性肺疾病(COPD)。 除核心产品外，公司的管线还包括八种处於不同研发阶段的候选药物，其中五种为临床阶段候选药物，以及三种处於可进入临床试验申请阶段。候选药物目前均处於开发阶段。康诺亚引入达15名基石投资者，包括Invesco Ltd.、UBS Asset Management (Singapore)、Hillhouse Capital及Boyu Capital Opportunities Master Fund等，合共认购1.9亿美元股份。公司预计，以招股价中位数51.9元计，所得款项净额为28.64亿元，约60%用於核心及主要产品的研发及商业化；约15%将用於公司其他在研产品的临床前评估及临床开发；约15%支付公司新生产及研发设施的租赁付款；约10%用於公司的一般企业及营运资金用途。 (sw/u)~阿思达克财经新闻网址: www.aastocks.com\t\t\t\t\t\t\t\t\t </p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《新股消息》康诺亚生物(02162.HK)今日起招股  入场费26,918.55元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《新股消息》康诺亚生物(02162.HK)今日起招股  入场费26,918.55元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 09:54 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1107932&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>内地生物科技公司康诺亚生物-B(02162.HK)公布招股详情，计划发售5,826.45万股股份，当中约10%在港公开发售，招股价介乎50.5元至53.3元，每手500股，入场费26,918.55元，由今日(25日)起至下周三(30日)公开招股，预计於7月8日上市。摩根士丹利、中金及华泰国际为联席保荐人。公司专注於自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法，核心产品CM310，用於治疗多种...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1107932&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/d17cb0ea313437e7afb8bad7f25dce9a","relate_stocks":{"02162":"康诺亚-B"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1107932&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2146802114","content_text":"内地生物科技公司康诺亚生物-B(02162.HK)公布招股详情，计划发售5,826.45万股股份，当中约10%在港公开发售，招股价介乎50.5元至53.3元，每手500股，入场费26,918.55元，由今日(25日)起至下周三(30日)公开招股，预计於7月8日上市。摩根士丹利、中金及华泰国际为联席保荐人。公司专注於自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法，核心产品CM310，用於治疗多种过敏性疾病，如中重度特应性皮炎(AD)、中重度嗜酸性哮喘和慢性鼻窦炎伴鼻息肉(CRSwNP)以及潜在慢性阻塞性肺疾病(COPD)。 除核心产品外，公司的管线还包括八种处於不同研发阶段的候选药物，其中五种为临床阶段候选药物，以及三种处於可进入临床试验申请阶段。候选药物目前均处於开发阶段。康诺亚引入达15名基石投资者，包括Invesco Ltd.、UBS Asset Management (Singapore)、Hillhouse Capital及Boyu Capital Opportunities Master Fund等，合共认购1.9亿美元股份。公司预计，以招股价中位数51.9元计，所得款项净额为28.64亿元，约60%用於核心及主要产品的研发及商业化；约15%将用於公司其他在研产品的临床前评估及临床开发；约15%支付公司新生产及研发设施的租赁付款；约10%用於公司的一般企业及营运资金用途。 (sw/u)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":792,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":25,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/122462210"}